Ian Neeland, MD Yeah, and I definitely think thats a real concern
The kind people notice without knowing why
According to incomplete statistics, sales of Novo Nordisk's semaglutide have been soaring year after year, with 2023 sales surpassing $21.2 billion, making it the first GLP-1 drug to join the "billion-dollar club." Its market position is quickly catching up with Merck's Keytruda, and it has the potential to become the next "blockbuster" drug
The personal care they offer is excellent and I doubt it can be matched anywhere else
Wegovy is more effective but costs significantly more (starting at 229/month vs Orlistats 18-44/month)
Instead of making GLP-1 tracking feel like another spreadsheet or macro program, MeAgain gives users a friendlier way to stay engaged with shot day, food noise, protein, hydration, side effects, progress, and consistency